PCF11 cleavage and polyadenylation factor subunitGenealiases: []
Q-omics provides the consensus-scored PCF11 profile across patient tissues and cancer cell-line models. PCF11 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PCF11 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, PCF11 RNA expression shows 21,475 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, THCA, and ACC as cancer lineages where PCF11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCF11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCF11 survival associations across molecular data types. PCF11 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCF11 RNA expression–survival associations across cancer types. High PCF11 expression shows unfavorable associations in ACC, but favorable associations in HNSC, SCLC, BLCA, UCS and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PCF11 RNA expression.
This table summarizes PCF11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PCF11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCF11 shows lower tumor expression in THCA, KICH, LUSC, HNSC and LUAD and higher tumor expression in LIHC. The THCA box plot shows higher PCF11 RNA expression in normal versus tumor tissue (log2 FC = −1.117, t-test p < 0.001).
This table shows molecular features associated with PCF11 in patient tissues and cancer cell lines. In patient samples, PCF11 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PCF11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
